Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC

Blood (2024) 144 (Supplement 1): 405.

https://doi.org/10.1182/blood-2024-210022

Published: 2024

Journal Articles

Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 5148.

https://doi.org/10.1182/blood-2024-210442

Published: 2024

Journal Articles

Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Isabel Lira, Danielle C. Kirkey, Marilena Nicolaidou, Henrike Muller, Marta Barisa, Melia Blankenfeld, Grace Hawkins, Cyd McKay, Christina Root, Laura Pardo, Michael R. Loken, Tiffany Hylkema, Concetta Quintarelli, Franco Locatelli, John Anderson, Soheil Meshinchi

Blood (2024) 144 (Supplement 1): 4793.

https://doi.org/10.1182/blood-2024-206227

Published: 2024

Journal Articles

Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia

Grace Hawkins, Danielle Kirkey, Nika Panahi, Melia Blankenfeld, Isabel Lira, Tiffany Hylkema, Cyd McKay, Christina Root, Jack H. Peplinski, Logan K. Wallace, Rhonda E. Ries, Laura Pardo, Michael R. Loken, Soheil Meshinchi

Blood (2024) 144 (Supplement 1): 3413.

https://doi.org/10.1182/blood-2024-204043

Published: 2024

Journal Articles

Potent and Target Specific Cytotoxicity of PRAME TCR Mimic CAR T Cells in KMT2A-Rearranged AML Patient-Derived Xenograft Model

Danielle C Kirkey, Leila Robinson, Tiffany Hylkema, Anisha Loeb, Rhonda E Ries, Cyd McKay, Christina Root, Laura Pardo, Keith R. Loeb, Quy Le, David A. Scheinberg, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 4821.

https://doi.org/10.1182/blood-2023-188391

Published: 2023

Journal Articles

Frailty Syndrome in Adults Undergoing Autologous Hematopoietic Cell Transplantation. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

Blood (2023) 142 (Supplement 1): 3702.

https://doi.org/10.1182/blood-2023-185679

Published: 2023

Journal Articles

The Frailty Syndrome As Predictor of Allogeneic Hematopoietic Cell Transplantation Outcomes. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

Blood (2023) 142 (Supplement 1): 2346.

https://doi.org/10.1182/blood-2023-190352

Published: 2023

Journal Articles

CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate

Danielle C Kirkey, Melia Blankenfeld, Tiffany Hylkema, Deryk Loo, Ashley Ward, Leila Robinson, Jack H Peplinski, Logan K Wallace, Laura Pardo, Andrew J. Menssen, Rhonda E Ries, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 5958.

https://doi.org/10.1182/blood-2023-187450

Published: 2023

Journal Articles

CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children's Oncology Group AAML1031 Protocol

Andrew J. Menssen, Chad A. Hudson, Todd A. Alonzo, Robert B. Gerbing, Laura Pardo, Fan-Chi Hsu, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, Yi-Cheng Wang, E. Anders Kolb, Todd M. Cooper, Jessica A. Pollard, Michael R. Loken, Richard Aplenc, Lisa Eidenschink Brodersen, Soheil Meshinchi

Blood (2022) 140 (Supplement 1): 3452–3453.

https://doi.org/10.1182/blood-2022-163682

Published: 2022

Journal Articles

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor Natural Killer Cell Therapy in Acute Myeloid Leukemia

Thao T. Tang, Lindsey F Call, Sommer Castro, Cynthia Nourigat-Mckay, LaKeisha Perkins, Laura Pardo, Amanda R. Leonti, Soheil Meshinchi, Quy Le

Blood (2021) 138 (Supplement 1): 1712.

https://doi.org/10.1182/blood-2021-153156

Published: 2021

Journal Articles

Project Stella: Development and Preclinical Assessment of FOLR1-Directed Chimeric Antigen Receptor T Cells in CBF2AT3-GLIS2/RAM AML

Quy Le, Sommer Castro, Thao T. Tang, Cynthia Nourigat-Mckay, LaKeisha Perkins, Tiffany A. Hylkema, Laura Pardo, Jenny L. Smith, Amanda R. Leonti, Rhonda E. Ries, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 2788.

https://doi.org/10.1182/blood-2021-151836

Published: 2021

Journal Articles

Immunotherapeutic Targeting of TSLPR with Chimeric Antigen Receptor T Cells in AML

Lindsey F Call, Sommer Castro, Thao T. Tang, Cynthia Nourigat-Mckay, LaKeisha Perkins, Laura Pardo, Amanda R. Leonti, Soheil Meshinchi, Quy Le

Blood (2021) 138 (Supplement 1): 2789.

https://doi.org/10.1182/blood-2021-153815

Published: 2021

Journal Articles

Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL

Quy Le, Amanda R. Leonti, Thao T. Tang, Sommer Castro, Cynthia Nourigat-Mckay, LaKeisha Perkins, Rhonda E. Ries, Jenny L. Smith, Tiffany A. Hylkema, Laura Pardo, Cristina Abrahams, Kristin Bedard, Arturo Molina, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 509.

https://doi.org/10.1182/blood-2021-151160

Published: 2021

Journal Articles

Increased Expression of CD56 on Plasmacytoid Dendritic Cells in Myeloid Leukemia Associated with Down Syndrome (ML-DS) Is Normal Regeneration and Not Measurable Residual Disease

Chad A Hudson, Laura Pardo, Loren L. Lott, Michael R. Loken, Lisa Eidenschink Brodersen

Blood (2021) 138 (Supplement 1): 3433.

https://doi.org/10.1182/blood-2021-149873

Published: 2021

Journal Articles

Targeting PRAME with TCR-Mimic CAR T Cells in AML

Anisha M Loeb, Sommer Castro, Cynthia Nourigat-Mckay, LaKeisha Perkins, Laura Pardo, Amanda R. Leonti, Thao T. Tang, Lindsey F Call, Tiffany A. Hylkema, David A. Scheinberg, Soheil Meshinchi, Quy Le

Blood (2021) 138 (Supplement 1): 733.

https://doi.org/10.1182/blood-2021-148677

Published: 2021

Journal Articles

Epigenetic Silencing of CD34 in AML and Association with Outcome in KMT2A Fusions

Rhonda E. Ries, Lisa Eidenschink Brodersen, Laura Pardo, Timothy Junius Triche, Jr., Amanda R. Leonti, Jenny L. Smith, Todd A. Alonzo, Jason E Farrar, Yi-Cheng Wang, Alice Dang, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 802.

https://doi.org/10.1182/blood-2021-149210

Published: 2021

Journal Articles

Endothelial Cell Niche Promotes Leukemic Transformation of Human Cord Blood Stem/Progenitor Cells Expressing CBFA2T3-GLIS2 Oncogenic Fusion

Quy Le, Tiffany A. Hylkema, Sommer Castro, Jenny L. Smith, Amanda R. Leonti, Thao T. Tang, Cynthia Nourigat-Mckay, LaKeisha Perkins, Laura Pardo, Lisa Eidenschink Brodersen, Michael R. Loken, Rhonda E. Ries, Keith R. Loeb, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 360.

https://doi.org/10.1182/blood-2021-148916

Published: 2021

Journal Articles

Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate

Quy Le, Jenny L. Smith, Thao T. Tang, Sommer Castro, Cynthia Nourigat-Mckay, LaKeisha Perkins, Benjamin J. Huang, Rhonda E. Ries, Amanda R. Leonti, Tiffany A. Hylkema, Laura Pardo, Cristina Abrahams, Kristin Bedard, Arturo Molina, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 209.

https://doi.org/10.1182/blood-2021-153076

Published: 2021

Journal Articles

CEBPA -bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group

Katherine Tarlock, Adam J. Lamble, Yi-Cheng Wang, Robert B. Gerbing, Rhonda E. Ries, Michael R. Loken, Lisa Eidenschink Brodersen, Laura Pardo, Amanda Leonti, Jenny L. Smith, Tiffany A. Hylkema, William G. Woods, Todd M. Cooper, E. Anders Kolb, Alan S. Gamis, Richard Aplenc, Todd A. Alonzo, Soheil Meshinchi

Blood (2021) 138 (13): 1137–1147.

https://doi.org/10.1182/blood.2020009652

Published: 2021

Includes: Supplemental data

Journal Articles

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

Quy Le, PhD, Sommer Castro, BS, Thao T. Tang, Anisha Loeb, BA, Amanda R. Leonti, MS, Laura Pardo, Michael R. Loken, PhD, Colin Correnti, PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-143140

Published: 2020

NARROW

The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC

Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia

Potent and Target Specific Cytotoxicity of PRAME TCR Mimic CAR T Cells in KMT2A-Rearranged AML Patient-Derived Xenograft Model

Frailty Syndrome in Adults Undergoing Autologous Hematopoietic Cell Transplantation. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

The Frailty Syndrome As Predictor of Allogeneic Hematopoietic Cell Transplantation Outcomes. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate

CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children's Oncology Group AAML1031 Protocol

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor Natural Killer Cell Therapy in Acute Myeloid Leukemia

Project Stella: Development and Preclinical Assessment of FOLR1-Directed Chimeric Antigen Receptor T Cells in CBF2AT3-GLIS2/RAM AML

Immunotherapeutic Targeting of TSLPR with Chimeric Antigen Receptor T Cells in AML

Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL

Increased Expression of CD56 on Plasmacytoid Dendritic Cells in Myeloid Leukemia Associated with Down Syndrome (ML-DS) Is Normal Regeneration and Not Measurable Residual Disease

Targeting PRAME with TCR-Mimic CAR T Cells in AML

Epigenetic Silencing of CD34 in AML and Association with Outcome in KMT2A Fusions

Endothelial Cell Niche Promotes Leukemic Transformation of Human Cord Blood Stem/Progenitor Cells Expressing CBFA2T3-GLIS2 Oncogenic Fusion

Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate

CEBPA -bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only